Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study tests a drug called A166 in 40 adults with HER2-positive breast cancer that has spread and no longer responds to standard treatments. Participants must have already tried a type of antibody-drug conjugate (TOP1-ADC). The goal is to see if A166 can shrink tumors or slow…

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer). About 420 adults who have …

This early-stage study tests a new drug called SKB571 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. About 138 participants will receive the drug, and research…

This study tests a new drug called SKB264 as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. About 524 participants will receive either SKB264 or standard chemotherapy. The goal is to see if SKB264 helps …

This study tests a new drug called SKB264 against standard chemotherapy for people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to hormone therapy. About 430 adults aged 18-75 will be randomly assigned to receive either SKB264 o…

This study tests whether adding an experimental drug (SKB264) to standard immunotherapy (pembrolizumab) works better than chemotherapy plus immunotherapy for people with advanced non-squamous lung cancer that lacks a key protein (PD-L1 negative). About 432 adults whose cancer has…

This early-stage study tests a new drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors or…

This study tests a new experimental drug called SKB518 in 150 adults with advanced solid tumors that have stopped responding to standard treatments or have no effective therapy. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Pa…

This early-phase trial is testing a new drug called SKB107 in people with advanced solid tumors that have spread to the bone. The main goals are to check the drug's safety and how the body processes it. About 90 adults aged 18-75 who have exhausted standard treatments may join. T…

This study tests a new drug called SKB264 against standard chemotherapy in people with advanced HR+/HER2- breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if SKB264 can slow cancer growth or improve survival. About 376 adults aged 18-75 …

This early-stage study tests a new medicine called SKB575 in 90 people, first in healthy volunteers and then in those with moderate-to-severe atopic dermatitis (eczema). The main goals are to check safety and see if it can reduce eczema symptoms like redness and itching. Particip…